The content on this site is intended for healthcare professionals only
Latest in combination therapy for NDMM patients
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
12 Dec 2021
Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail pa...
Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy
11 Dec 2021
Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neop...
Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA
11 Dec 2021
Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in ...
Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
11 Dec 2021
Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA
11 Dec 2021
ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-...
Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston...
11 Dec 2021
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL
Prof Brian Hill - Cleveland Clinic, Cleveland, USA
11 Dec 2021
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma
Prof Elizabeth Budde - City of Hope, Duarte, USA
11 Dec 2021
Study indicates circulating tumour cell assessment should be part of multiple my...
Dr Juan-José Garcés - Clinica Universidad de Navarra, Pamplona, Spain
11 Dec 2021
Initial treatment options for relapsed/refractory multiple myeloma patients
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Sp...
11 Dec 2021
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iN...
Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston...
11 Dec 2021
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LB...
Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, U...
11 Dec 2021